Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...
In a report released on January 30, Florian Treisch from Kepler Capital maintained a Buy rating on Sage Group plc (SGE – Research Report), ...
Sage Group PLC hit a new 52-week high, surpassing its previous peak of £13.42, which the company reached on January 22nd.
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it ...
Jefferies raised the firm’s price target on Sage Group (SGPYY) to 1,600 GBp from 1,500 GBp and keeps a Buy rating on the shares. The “most ...
3don MSN
Research photo from the National Cancer Institute, shared via Unsplash. (NCI Photo) When Luca Foschini, head of Seattle's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback